{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:21:31Z","timestamp":1779366091264,"version":"3.53.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ctrv.2023.102674","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T03:43:11Z","timestamp":1703302991000},"page":"102674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Histology independent drug development \u2013 Is this the future for cancer drugs?"],"prefix":"10.1016","volume":"123","author":[{"given":"Lucinda","family":"Billingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodor","family":"Framke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Hovig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Pean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Barjesteh van Waalwijk van Doorn-Khosrovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richardus","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Wissink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilke","family":"Zander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-1444","authenticated-orcid":false,"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102674_b0005","unstructured":"U.S. Food Drug Adm. Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/tissue-agnostic-drug-development-oncology (2022)."},{"key":"10.1016\/j.ctrv.2023.102674_b0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2023.102674_b0015","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdz119","article-title":"Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients","volume":"30","author":"van Waalwijk van Doorn-Khosrovani, S. B.","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0020","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0025","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF -mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2023.102674_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0040","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/annonc\/mdz134","article-title":"Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer","volume":"30","author":"Schrock","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(21)00707-5","article-title":"Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform","volume":"23","author":"Zeverijn","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The drug rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2023.102674_b0055","unstructured":"Zorginstituut Ned. Standpunt nivolumab (Opdivo\u00ae) voor de behandeling van bepaalde pati\u00ebnten met dMMR- of MSI-tumoren. https:\/\/www.zorginstituutnederland.nl\/publicaties\/standpunten\/2022\/06\/23\/standpunt-nivolumab-opdivo-bij-dmmr--of-msi-tumoren (2022)."},{"key":"10.1016\/j.ctrv.2023.102674_b0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0065","doi-asserted-by":"crossref","first-page":"S780","DOI":"10.1016\/j.annonc.2022.07.646","article-title":"518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1\/2 mutation","volume":"33","author":"Oza","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0070","unstructured":"Eur. Med. Agency. EMA recommends restricting use of cancer medicine Rubraca. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-restricting-use-cancer-medicine-rubraca (2022)."},{"key":"10.1016\/j.ctrv.2023.102674_b0075","article-title":"Drugmaker pulls third-line PARP inhibitor approval in ovarian cancer","author":"Basset","year":"2022","journal-title":"Medpage Today"},{"key":"10.1016\/j.ctrv.2023.102674_b0080","doi-asserted-by":"crossref","first-page":"11529","DOI":"10.3390\/ijms231911529","article-title":"Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection","volume":"23","author":"Lonardi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2023.102674_b0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102674_b0090","unstructured":"Pers. Cancer Med. All EU Citizens. The first PCM4EU podcast episodes are now available. https:\/\/www.matrix-fkb.no\/en\/pcm4eu-news\/the-first-pcm4eu-podcast-episodes-are-now-available (2023)."},{"key":"10.1016\/j.ctrv.2023.102674_b0095","unstructured":"DETERMINE Precision Medicine. https:\/\/www.cancerresearchuk.org\/funding-for-researchers\/our-research-infrastructure\/our-centre-for-drug-development\/determine-overview."},{"key":"10.1016\/j.ctrv.2023.102674_b0100","unstructured":"Eur. Med. Agency. Accelerating Clinical Trials in the EU (ACT EU). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/clinical-trials\/accelerating-clinical-trials-eu-act-eu (2022)."},{"key":"10.1016\/j.ctrv.2023.102674_b0105","unstructured":"Eur. Comm. eur. Med. Agency \/ Head Med. Agency. Complex clinical trials \u2013 Questions and answers. https:\/\/health.ec.europa.eu\/system\/files\/2022-06\/medicinal_qa_complex_clinical-trials_en.pdf (22AD)."},{"key":"10.1016\/j.ctrv.2023.102674_b0110","unstructured":"Eur. Med. Agency. Concept paper on platform trials. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/concept-paper-platform-trials_en.pdf (2022)."},{"issue":"suppl_2","key":"10.1016\/j.ctrv.2023.102674_b0115","first-page":"S925","article-title":"The DRUP-like clinical trials family: a distributed European trial network for equitable access to precision medicine","volume":"34","author":"Gelderblom","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102674_b0120","unstructured":"Eur. Comm. European Cancer Inequalities Registry. https:\/\/cancer-inequalities.jrc.ec.europa.eu\/."},{"key":"10.1016\/j.ctrv.2023.102674_b0125","unstructured":"Eur. Comm. European Health Data Space. https:\/\/health.ec.europa.eu\/ehealth-digital-health-and-care\/european-health-data-space_en."},{"key":"10.1016\/j.ctrv.2023.102674_b0130","unstructured":"Knowles P, Page P, Mitwicki R. Decentralised semantics in distributed data ecosystems. The 8th Joint Ontology Workshops (JOWO\u201922), Aug.15-19 J\u00f6nk\u00f6ping University, Sweden https:\/\/ceur-ws.org\/Vol-3249\/paper4-OSS.pdf."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223001676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:30:41Z","timestamp":1759656641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223001676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":26,"alternative-id":["S0305737223001676"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102674","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histology independent drug development \u2013 Is this the future for cancer drugs?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102674"}}